On the contrary, patients who do not have any negative emotional impact may start to present anxiety and stress when they experience AH.
De Miranda et al. [ 35] found that on day 5 PoI PbA-infected mice presented anxiety signs, histopathological alterations in the brainstem, cerebrum, and hippocampus, and increased cerebral levels of proinflammatory cytokines.
Patients with an accumulation of psychosocial stressors were more likely to present anxiety, depression, or somatoform disorders, with an increase of 2.2 fold (95% CI = 2.0 to 2.5) for each additional stressor.
In a recent experiment Prehn-Kirstensen and colleges presented anxiety-induced and sport-condition sweat samples to 28 participants and collected fMRI data during presentation.
At the postnatal phase, anxiety prevalence was higher with 20.2% (35/173) of women presenting severe anxiety symptoms and 24.3% (N = 42/173) moderate anxiety symptoms.
Moreover, two months after birth, women with severe anxiety had significantly more difficulties in positive reframing of their new situation than women presenting no anxiety.
Detecting and addressing cannabis use in patients presenting with anxiety disorders might also be important because cannabinoids could theoretically interact with any pharmacological treatment for anxiety.
The management of patients presenting with anxiety symptoms should initially follow the flow of the five main components outlined in Table 3. Anxiety and related disorders are generally characterized by the features of excessive anxiety, fear, worry, and avoidance.
